M&A Deal Summary

UNION therapeutics A/S Acquires LEO PDE4 Inhibitor

On July 21, 2020, UNION therapeutics A/S acquired life science company LEO PDE4 Inhibitor from LEO Pharma for 200M USD

Acquisition Highlights
  • This is UNION therapeutics A/S’s 1st transaction in the Life Science sector.
  • This is UNION therapeutics A/S’s largest (disclosed) transaction.
  • This is UNION therapeutics A/S’s 1st transaction in Denmark.

M&A Deal Summary
Date 2020-07-21
Target LEO PDE4 Inhibitor
Sector Life Science
Buyer(s) UNION therapeutics A/S
Sellers(s) LEO Pharma
Deal Type Divestiture
Deal Value 200M USD

Target

LEO PDE4 Inhibitor

Ballerup, Denmark
LEO PDE4 Inhibitor compound series has the potential for the treatment of psoriasis and other immune-dermatological disorders.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

UNION therapeutics A/S

Hellerup, Denmark
Category Company
Sector Life Science
DESCRIPTION

UNION therapeutics A/S is a privately held, clinical-stage pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and the USA.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Denmark) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

LEO Pharma

Ballerup, Denmark
Category Company
Founded 1908
Sector Life Science
Employees4,285
Revenue 1.4B EUR (2022)
DESCRIPTION

LEO Pharma engages in medical dermatology with a robust R&D pipeline, a wide range of therapies, and a pioneering spirit. LEO Pharma supports people in managing their skin conditions. LEO Pharma was founded in 1908 and is based in Ballerup, Denmark.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Denmark) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-11-11 Astellas Pharma - Global Dermatology

United States

Astellas Pharma - Global Dermatology is a provider of pharmaceutical services.

Buy €675M
Mergr

Product

Company

Legal